Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Velcade Therapy for Severe IgA Nephropathy

NCT01103778 is registered in ClinicalTrials.gov with The Rogosin Institute as lead sponsor.

NCT NCT01103778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01103778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Velcade Therapy for Severe IgA Nephropathy
Lead sponsor
The Rogosin Institute
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2010
Completion date
April 17, 2017
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, iga nephropathy